Free Trial

Sonoma Pharmaceuticals (SNOA) Competitors

Sonoma Pharmaceuticals logo
$3.83 -0.25 (-6.13%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$3.94 +0.11 (+2.87%)
As of 10/17/2025 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SNOA vs. CVKD, ENLV, XCUR, LPTX, MTVA, PASG, PRPH, ALLR, MIRA, and TAOX

Should you be buying Sonoma Pharmaceuticals stock or one of its competitors? The main competitors of Sonoma Pharmaceuticals include Cadrenal Therapeutics (CVKD), Enlivex Therapeutics (ENLV), Exicure (XCUR), Leap Therapeutics (LPTX), MetaVia (MTVA), Passage Bio (PASG), ProPhase Labs (PRPH), Allarity Therapeutics (ALLR), MIRA Pharmaceuticals (MIRA), and Synaptogenix (TAOX). These companies are all part of the "pharmaceutical products" industry.

Sonoma Pharmaceuticals vs. Its Competitors

Sonoma Pharmaceuticals (NASDAQ:SNOA) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 24.6% of Sonoma Pharmaceuticals shares are owned by insiders. Comparatively, 26.1% of Cadrenal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Sonoma Pharmaceuticals has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

In the previous week, Cadrenal Therapeutics had 4 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 5 mentions for Cadrenal Therapeutics and 1 mentions for Sonoma Pharmaceuticals. Sonoma Pharmaceuticals' average media sentiment score of 0.34 beat Cadrenal Therapeutics' score of -0.43 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sonoma Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cadrenal Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Cadrenal Therapeutics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -23.87%. Sonoma Pharmaceuticals' return on equity of -50.00% beat Cadrenal Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Sonoma Pharmaceuticals-23.87% -50.00% -16.79%
Cadrenal Therapeutics N/A -265.37%-196.38%

Sonoma Pharmaceuticals has higher revenue and earnings than Cadrenal Therapeutics. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sonoma Pharmaceuticals$14.29M0.44-$3.46M-$2.46-1.56
Cadrenal TherapeuticsN/AN/A-$10.65M-$8.88-1.53

Cadrenal Therapeutics has a consensus price target of $32.00, indicating a potential upside of 134.78%. Given Cadrenal Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cadrenal Therapeutics is more favorable than Sonoma Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sonoma Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Cadrenal Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Cadrenal Therapeutics beats Sonoma Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Sonoma Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SNOA vs. The Competition

MetricSonoma PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$6.71M$2.62B$6.09B$10.48B
Dividend YieldN/A57.79%5.73%4.80%
P/E Ratio-1.5622.9984.5227.09
Price / Sales0.44565.31519.33179.64
Price / CashN/A168.7137.1661.22
Price / Book1.405.3212.246.52
Net Income-$3.46M$33.06M$3.32B$276.75M
7 Day Performance-5.20%2.44%1.26%1.97%
1 Month Performance-10.09%6.46%6.29%2.23%
1 Year Performance21.20%-5.42%59.93%35.58%

Sonoma Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SNOA
Sonoma Pharmaceuticals
1.0902 of 5 stars
$3.83
-6.1%
N/A+30.7%$6.71M$14.29M-1.56180News Coverage
Gap Up
CVKD
Cadrenal Therapeutics
2.9076 of 5 stars
$13.58
+0.4%
$32.00
+135.6%
-16.4%$27.84MN/A-1.534
ENLV
Enlivex Therapeutics
2.6921 of 5 stars
$1.13
-1.7%
$10.00
+788.9%
-35.0%$27.33MN/A-1.9470News Coverage
XCUR
Exicure
1.1733 of 5 stars
$4.27
-0.1%
N/A+56.0%$26.92M$500K-1.1050
LPTX
Leap Therapeutics
2.8345 of 5 stars
$0.63
-17.4%
$3.38
+434.9%
-76.3%$26.19MN/A-0.4040News Coverage
Positive News
Analyst Downgrade
Short Interest ↓
Gap Up
High Trading Volume
MTVA
MetaVia
1.6265 of 5 stars
$1.05
-2.8%
$7.50
+614.3%
N/A$25.41MN/A0.008
PASG
Passage Bio
3.0958 of 5 stars
$7.96
+0.3%
$75.67
+851.2%
-32.3%$25.29MN/A-0.44130
PRPH
ProPhase Labs
0.6692 of 5 stars
$0.61
+2.0%
N/A-79.5%$25.26M$6.77M-0.48130Positive News
Gap Up
ALLR
Allarity Therapeutics
2.2175 of 5 stars
$1.74
+5.2%
$9.25
+433.1%
-15.8%$25.18MN/A0.0010Gap Down
MIRA
MIRA Pharmaceuticals
0.3656 of 5 stars
$1.31
-3.0%
N/A+48.6%$24.98MN/A-2.672News Coverage
Gap Down
TAOX
Synaptogenix
0.0603 of 5 stars
$7.08
-8.2%
N/AN/A$24.71MN/A-0.354News Coverage
Gap Up

Related Companies and Tools


This page (NASDAQ:SNOA) was last updated on 10/18/2025 by MarketBeat.com Staff
From Our Partners